Podcasts

E-Books

Videos

Articles

Clinical

Tony Hagen is senior managing editor for The Center for Biosimilars

Calls for price regulation and lopsided incentives are threats to biosimilar progress, Community Oncology Alliance (COA) Executive Director Ted Okon argues.

COA's Okon Takes Aim at Biosimilar Misconceptions

PlantForm will use tobacco plants to develop antibodies for its checkpoint inhibitor pembrolizumab biosimilar.  

PlantForm Will Challenge Merck's Dominance for Pembrolizumab

Shanghai Henlius Biotech began as a 2-person enterprise in 2010 and now has multiple oncology products in development and 3 biosimilars on the market. An executive discusses its business trajectory.

Shanghai Henlius Biotech Maps Out Its Biosimilars Future

Sarfaraz K. Niazi, PhD, is an adjunct professor of biopharmaceutical sciences at the University of Illinois and the University of Houston, and founder of biosimilars companies Karyo Biologics and Adello Biologics. He also founded the biosimilar advisory company PharmSci.

Sarfaraz K. Niazi, PhD, a member of The Center for Biosimilars® Advisory Board, recounts a debate with a young clinician over the reliability of biosimilarity testing. 

Column: A Biosimilars Dialogue With a Young Clinician

Seeking to develop a biosimilar portfolio, Stada Arzneimittel has launched Oyavas in Germany and the Netherlands. 

Stada Launches Bevacizumab Biosimilar

Potential developers of orphan drug biosimilars face daunting challenges to get these drugs approved and onto market, said a panel of experts. 

Are Orphan Drug Biosimilars Too Costly and Difficult to Produce?

EirGenix, in partnership with Sandoz, announced positive safety and efficacy results for its trastuzumab biosimilar in patients with breast cancer.

Phase 3 Trial Demonstrates Bioequivalence for EirGenix’s Trastuzumab Biosimilar Candidate 

A renowned expert on the life sciences industry in the United Kingdom provides an insightful look at Brexit and the importance for the pharmaceutical sector. 

The Brexit Rollout From the Biosimilars Perspective

A panel of physicians gave advice on how biosimilar educational materials should instill confidence in these medications and which policies may be more harmful than beneficial.

What Should Educational Materials Include to Instill Confidence in Biosimilars?

Biosimilars get short shrift in a proposed pricing model developed by the Drug Pricing Lab at Memorial Sloan Kettering (MSK), experts say. 

Oncology